{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/management/assessment/","result":{"pageContext":{"chapter":{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment","depth":2,"htmlHeader":"<!-- begin field 01f9906b-f194-4af8-a966-a71301203efd --><h2>Scenario: Assessment</h2><!-- end field 01f9906b-f194-4af8-a966-a71301203efd -->","summary":"Covers the assessment of the physical severity of atopic eczema as well as the psychological impact of atopic eczema.","htmlStringContent":"<!-- begin item 1f191e0c-5944-4cf1-966c-a71301203d00 --><!-- begin field 4fe353ea-4688-44a8-b27e-acbd00858150 --><p>From age 1 month onwards.</p><!-- end field 4fe353ea-4688-44a8-b27e-acbd00858150 --><!-- end item 1f191e0c-5944-4cf1-966c-a71301203d00 -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"aa1500fd-2da0-51fc-8813-7b2dd90463c0","slug":"assessing-severity-of-atopic-eczema","fullItemName":"Assessing severity of atopic eczema","depth":3,"htmlHeader":"<!-- begin field 0de82e4a-7e25-43cd-a3eb-a71301203f02 --><h3>How should I assess the severity of eczema?</h3><!-- end field 0de82e4a-7e25-43cd-a3eb-a71301203f02 -->","summary":null,"htmlStringContent":"<!-- begin item 89d2d56a-3c7a-402d-aab2-a71301203f02 --><!-- begin field d59a9a20-1f3b-4678-987f-a71301203f02 --><ul><li><strong>At each consultation, assess the severity of the eczema in order to determine the most appropriate treatment.</strong><ul><li><strong>To assess the severity of the eczema, </strong>examine all areas of affected skin, and ask about itching.</li><li>Categorize eczema as:<ul><li>Clear — if there is normal skin and no evidence of active eczema. </li><li>Mild — if there are areas of dry skin, and infrequent itching (with or without small areas of redness). See <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/mild-eczema/\">Scenario: Mild eczema</a> for management information.</li><li>Moderate — if there are areas of dry skin, frequent itching, and redness (with or without excoriation and localized skin thickening). See <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/moderate-eczema/\">Scenario: Moderate eczema</a> for management information.</li><li>Severe — if there are widespread areas of dry skin, incessant itching, and redness (with or without excoriation, extensive skin thickening, bleeding, oozing, cracking, and alteration of pigmentation). See <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/severe-eczema/\">Scenario: Severe eczema</a> for management information.</li><li>Infected — if eczema is weeping, crusted, or there are pustules, with fever or malaise. See <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/infected-eczema/\">Scenario: Infected eczema</a> for management information.</li></ul></li><li>Consider using validated tools to assess severity. For example, using visual analogue scales (0–10) of the person's assessment of severity, itch, and sleep loss over the last 3 days and nights, or using the Patient-Oriented Eczema Measure (which can be downloaded from <a href=\"http://www.nottingham.ac.uk/research/groups/cebd/resources/poem.aspx\" data-hyperlink-id=\"0b05565e-1e59-4d70-8113-a8f7015b76ac\">www.nottingham.ac.uk (pdf)</a>).</li></ul></li></ul><!-- end field d59a9a20-1f3b-4678-987f-a71301203f02 --><!-- end item 89d2d56a-3c7a-402d-aab2-a71301203f02 -->","subChapters":[{"id":"8aff55fd-49df-5a94-9282-857bf03631f1","slug":"basis-for-recommendation-c79","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 639549ad-effe-4cec-a5fd-a71301203f07 --><h4>Basis for recommendation</h4><!-- end field 639549ad-effe-4cec-a5fd-a71301203f07 -->","summary":null,"htmlStringContent":"<!-- begin item c7930727-478d-467d-b005-a71301203f07 --><!-- begin field 5b0c53ad-bc16-4b25-bdd6-a71301203f07 --><p>These recommendations are largely based on expert opinion in the National Institute for Health and Care Excellence (NICE) guideline <em>Atopic eczema in under 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].<strong> </strong>NICE reviewed this guideline in July 2016 and found no new evidence to warrant a change in recommendations. CKS has extrapolated the recommendations to include the management of older children and adults. </p><ul><li>Expert opinion in the NICE guideline is that an examination of all patches of eczema is needed as differing severity can co-exist on the same person, requiring independent treatment. Physical examination is also essential to determine the correct treatment.</li><li>The NICE Guideline Development Group (GDG) could not find any evidence on the usefulness of severity and quality of life measures for guiding treatment decisions in clinical practice. However, the GDG agreed that a structured, validated tool may prompt individuals and families about certain aspects of the condition, thereby improving communication and treatment.</li></ul><!-- end field 5b0c53ad-bc16-4b25-bdd6-a71301203f07 --><!-- end item c7930727-478d-467d-b005-a71301203f07 -->","subChapters":[]}]},{"id":"d45835cc-b998-5256-8893-d9d5c1fa7137","slug":"assessing-psychological-impact","fullItemName":"Assessing psychological impact","depth":3,"htmlHeader":"<!-- begin field 3bababfd-b96d-4952-85e6-a713012305a2 --><h3>How should I assess the psychological impact of eczema?</h3><!-- end field 3bababfd-b96d-4952-85e6-a713012305a2 -->","summary":null,"htmlStringContent":"<!-- begin item 0400978d-10e5-4998-b983-a713012303a2 --><!-- begin field a39df08d-3673-4d61-b1c2-a713012305a2 --><ul><li><strong>At each consultation, </strong><strong>assess the psychological impact of atopic eczema. </strong>Be aware that there is not necessarily a direct relationship between the severity of the atopic eczema and the impact of the atopic eczema on quality of life.<ul><li><strong>To assess the psychological impact of atopic eczema, </strong>ask about the effect of eczema on daily activities (school, work, and social life), sleep, and mood.</li><li>Categorize the impact of eczema on quality of life and psychosocial well-being as:<ul><li>None — no impact on quality of life.</li><li>Mild — little impact on everyday activities, sleep, and psychosocial well-being.</li><li>Moderate — moderate impact on everyday activities and psychosocial well-being, and frequently disturbed sleep.</li><li>Severe — severe limitation of everyday activities and psychosocial functioning, and loss of sleep every night.</li></ul></li><li>Consider using questionnaires to give an objective measure of quality of life. For example, the Children's Dermatology Life Quality Index (CDLQI) and Adult's Dermatology Life Quality Index (ADLQI), Infant's Dermatitis Quality of Life index (IDQOL), or Dermatitis Family Impact questionnaire (DFI). For more information on quality of life questionnaires, see <a href=\"http://www.dermatology.org.uk/portal/quality/index.html\" data-hyperlink-id=\"be3754b4-3211-4b62-9df5-a8f7015c2ebc\">www.dermatology.org.uk</a>.</li></ul></li></ul><!-- end field a39df08d-3673-4d61-b1c2-a713012305a2 --><!-- end item 0400978d-10e5-4998-b983-a713012303a2 -->","subChapters":[{"id":"87b4dc01-2fd1-580a-96ad-867744fce064","slug":"basis-for-recommendation-aac","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6d07dcfc-2f0a-4ccc-95c3-a713012305a6 --><h4>Basis for recommendation</h4><!-- end field 6d07dcfc-2f0a-4ccc-95c3-a713012305a6 -->","summary":null,"htmlStringContent":"<!-- begin item aaca0e72-2ce3-476a-a46d-a713012305a6 --><!-- begin field 97a571e2-924d-40b8-885f-a713012305a6 --><p>These recommendations are largely based on expert opinion in the National Institute for Health and Care Excellence (NICE) guideline <em>Atopic eczema in under 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].<strong> </strong>NICE reviewed this guideline in July 2016 and found no new evidence to warrant a change in recommendations. CKS has extrapolated the recommendations to include the management of older children and adults. </p><ul><li>NICE states that an assessment of quality of life will help influence treatment choices and referral decisions. For example, if the person has only mild physical symptoms but is severely affected psychologically, a referral to secondary care is appropriate.</li></ul><!-- end field 97a571e2-924d-40b8-885f-a713012305a6 --><!-- end item aaca0e72-2ce3-476a-a46d-a713012305a6 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}